CN110714051B - Protein C activity determination kit - Google Patents
Protein C activity determination kit Download PDFInfo
- Publication number
- CN110714051B CN110714051B CN201911138203.6A CN201911138203A CN110714051B CN 110714051 B CN110714051 B CN 110714051B CN 201911138203 A CN201911138203 A CN 201911138203A CN 110714051 B CN110714051 B CN 110714051B
- Authority
- CN
- China
- Prior art keywords
- reagent
- protein
- buffer solution
- kit
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
Abstract
The invention relates to a protein C activity determination kit, which comprises: a reagent R1 containing a protein C activator and a reagent R2 containing a chromogenic substrate. The reagent R1 and the reagent R2 in the kit are both liquid, the preparation process is simple, the cost is low, the stability and the hemoglobin interference resistance effect are obviously improved, and the kit can be widely applied to institutions such as hospitals, health departments, medical biological research units and the like.
Description
Technical Field
The invention relates to the field of molecular biology, in particular to a protein C activity determination kit.
Background
Protein C (PC for short) is a plasma serine protease zymogen dependent on vitamin K, is mainly synthesized in the liver, can also be synthesized into a part in the kidney and the testis, has the relative molecular mass of 62kD, and has the half-life period of 6 hours. It is converted into activated protein C (APC for short) by thrombin or thrombin-thrombomodulin complex. APC and its cofactor protein S (PS for short) form the complex, have activity of inactivating Va and VIIIa and increasing fibrinolysis, therefore have anticoagulation effects. When PC is deficient, inactivation of factors Va and VIIIa decreases and the fibrinolytic capacity of the blood circulation decreases, thus contributing to excessive fibrin formation, resulting in thrombosis.
PC plays an important role in aspects of anticoagulation, anti-inflammation, anti-apoptosis, protection of vascular endothelial cells and the like, and has a plurality of biological functions, so that the PC is closely related to a plurality of clinical diseases. Such as sepsis, septicemia, disseminated Intravascular Coagulation (DIC), thrombotic diseases and liver diseases, such as cirrhosis and chronic hepatitis, a different degree of reduction in PC levels can be detected. Therefore, the determination of PC plays an important role in the prevention, monitoring and treatment of diseases. Therefore, the simple method for accurately detecting the activity of the PC in the blood plasma is established, and has important values for the prevention and diagnosis, the observation of the disease condition and the judgment of prognosis of various diseases.
Currently, the detection of protein C can be generally classified into 2 major categories: one is the measurement of its antigen content (PC: ag) and the other is the measurement of its activity (PC: AC).
PC: ag can be used for quantitative analysis of PC antigen by radioimmunoassay, rocket electrophoresis, enzyme-linked immunosorbent assay (ELISA), etc. The rocket electrophoresis method has poor specificity and low sensitivity and is limited by the preparation scale of antiserum, so the method has great limitation; radioimmunoassay methods require special instruments and are difficult to perform in common laboratories; therefore, the content of the polypeptide is generally measured by adopting an ELISA method with higher specificity and simpler operation.
PC: the AC can be measured by activated partial thromboplastin reagent method (APTT) and chromogenic substrate method (CSA). The determination of the measurement result of the APTT method is often determined by the experience of inspectors, and the accuracy and the repeatability of the measurement result are directly influenced. The CAS method adopts a specific chromogenic substrate, so that the operation is simple and convenient, and the accuracy and the repeatability of the measurement result are better.
Acquired PC deficiency patient PC: ag and PC: changes in AC are parallel, so PC: ag and PC: AC has the same clinical significance, and PC is generally measured by ELISA or Chromogenic Substrate Assay (CSA): ag or PC: and (6) AC.
The World Health Organization (WHO) recommends the PC detection method as a chromogenic substrate method (CSA). At present, the commercial protein C activity detection kit mainly adopts a chromogenic substrate method, the method can accurately and specifically reflect the PC activity, the result is real and stable, the operation is simple and easy, the method has the advantage of rapidness, and the detection can be completed in a few minutes.
The activator used in the current commercial protein C activity determination kit is mostly separated and purified from agkistrodon halys venom. However, the stability of the protein C activator extracted from the venom of Agkistrodon halys is poor, and in order to prolong the storage time of the reagent, in the currently marketed protein C activity determination kit, the reagent is all freeze-dried powder. However, lyophilized reagents have the following disadvantages: the preparation process is complicated and the cost is high; the difference between bottles of reagents is large; the freeze-dried reagent needs to be redissolved before actual use, and the operation is inconvenient; the re-dissolved reagent has poor stability and needs to be used in a short time, otherwise, the reagent is easy to waste.
Therefore, the liquid protein C activity assay kit which is simple to prepare, low in cost, good in stability, convenient to use and easy to popularize and use in hospitals and health departments at all levels is urgently needed in the field.
Disclosure of Invention
In order to solve the above problems, the present invention aims to provide a liquid-type protein C activity assay kit having good stability.
In a first aspect, the present invention provides a protein C activity assay kit comprising a reagent R1 and a reagent R2. The reagent R1 comprises a protein C activator, a buffer solution, polyethylene glycol, PC300 and an alcamines compound; the reagent R2 comprises a chromogenic substrate and a buffer solution.
PC300, proClin300, which comprises mainly 2-methyl-4-isothiazolin-3-one and 5-chloro-2-methyl-4-isothiazolin-3-one. An exemplary amount of PC300 is 0.5 to 10.0mL/L, and for example, 0.5mL/L, 1mL/L, 2mL/L, 3mL/L, 4mL/L, 5mL/L, 6mL/L, 7mL/L, 8mL/L, 9mL/L, or 10mL/L can be selected.
In some embodiments, reagent R1 has a pH of 7.2 to 8.5, for example, can be 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, or 8.5. In some embodiments, the reagent R2 has a pH of 6.0 to 7.2, for example, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, or 7.2.
In some embodiments, a protein C activator refers to a component extracted from Agkistrodon halys venom that specifically activates protein C. Exemplary amounts of protein C activator are 0.05 to 0.50IU/ml, and may be, for example, 0.05IU/ml, 0.1IU/ml, 0.15IU/ml, 0.2IU/ml, 0.25IU/ml, 0.3IU/ml, 0.35IU/ml, 0.4IU/ml, 0.45IU/ml, or 0.5IU/ml.
In some embodiments, the polyethylene glycol is selected from PEG-20000, PEG-4000, PEG-6000 in one or more combinations. In a further preferred embodiment, the polyethylene glycol is PEG-20000. Polyethylene glycol is illustratively used in an amount of 0.5 to 15.0g/L, and may be, for example, 0.5g/L, 1g/L, 2g/L, 3g/L, 4g/L, 5g/L, 6g/L, 7g/L, 8g/L, 9g/L, 10g/L, 11g/L, 12g/L, 13g/L, 14g/L, or 15g/L.
In some embodiments, the alkanolamine compound is selected from one or a combination of two or more of tromethamine, 2-amino-2-methyl-1-propanol, monoethanolamine, diethanolamine, triethanolamine, 3-propanolamine, monoisopropanolamine, diisopropanolamine, triisopropanolamine, N-dimethylethanolamine and N, N-diethylethanolamine. In a further preferred embodiment, the alkanolamine compound is one or a combination of two or more selected from the group consisting of tromethamine, triethanolamine and 2-amino-2-methyl-1-propanol. In a further preferred embodiment, the alkanolamine compound is triethanolamine. The alcoholamines are used in an exemplary amount of 1 to 40g/L, for example, 1g/L, 3g/L, 5g/L, 7g/L, 8g/L, 9g/L, 10g/L, 11g/L, 12g/L, 13g/L, 14g/L, 15g/L, 16g/L, 17g/L, 18g/L, 19g/L, 20g/L, 21g/L, 22g/L, 23g/L, 24g/L, 25g/L, 26g/L, 27g/L, 28g/L, 29g/L, 30g/L, 32g/L, 34g/L, 36g/L, 38g/L, 39g/L, 40g/L.
In some embodiments, the buffer in reagent R1 and reagent R2 is selected from one or a combination of two or more of HEPES acid buffer, tris buffer, imidazole buffer, barbiturate buffer. Exemplary amounts of buffer are 5.0 to 30.0g/L
In some embodiments, a stabilizer is also included in the agent R1. The stabilizer can be one or more of protein, saccharide, amino acid, antioxidant, and suspending agent. In a more preferred embodiment, the stabilizer is selected from one or a combination of two or more of bovine serum albumin, trehalose, mannitol and sorbitol. In a further preferred embodiment, the stabilizer is a combination of bovine serum albumin and trehalose. The amount of stabilizer is conventional in the art, for example, bovine serum albumin is illustratively used in an amount of 5.0 to 30.0g/L, and trehalose is illustratively used in an amount of 0.5 to 20.0g/L.
In some embodiments, the chromogenic substrate in reagent R2 is selected from one of PyroGlu-Pro-Arg-pNA HCl, p-glu-Pro-Arg-MNA, THC-Pro-Arg-pNA, and an exemplary amount of chromogenic substrate is 0.1 to 0.8mg/ml.
In some embodiments, an inorganic salt is also included in reagent R2. The inorganic salt may be selected from NaCl, KCl, or CSCl, and in certain embodiments, the inorganic salt is preferably CSCl. Exemplary amounts of inorganic salts are 1.0 to 30.0g/L.
In some embodiments, a stabilizer is also included in reagent R2. The stabilizer in the reagent R2 is similar to the stabilizer in the reagent R1, and can be one or the combination of more than two of protein, sugar, amino acid, antioxidant and suspending agent, wherein, the protein can be bovine serum albumin; the saccharide can be trehalose, mannitol, sorbitol, etc., and the amino acid can be histidine, arginine, etc. In certain embodiments, the stabilizing agent in agent R2 is arginine. Exemplary amounts of the stabilizer are 1.0 to 20.0g/L.
In some embodiments, a preservative is also included in agent R2. The preservative may be selected from one or more of the sodium azide (Na 3N), MIT (i.e., 2-methyl-4-isothiazolin-3-one), CMIT (i.e., 5-chloro-2-methyl-4-isothiazolin-3-one), phenol, proClin series. In certain embodiments, the preservative in reagent R2 is sodium azide. Exemplary amounts of preservatives are 0.1 to 10.0g/L.
In some embodiments, the protein C activity assay kit includes reagent R1 and reagent R2,
the reagent R1 comprises:
HEPES buffer solution: 5.0-30.0 g/L;
protein C activator: 0.05-0.50 IU/ml;
bovine serum albumin: 5.0-30.0 g/L;
trehalose: 0.5-20.0 g/L;
PEG-20000：0.5～15.0g/L；
PC300：0.5～10.0mL/L；
triethanolamine: 10-30 mL/L;
the reagent R2 comprises:
HEPES buffer solution: 5.0-30.0 g/L;
chromogenic substrate: 0.1-0.8 mg/ml;
a stabilizer: 1.0-20.0 g/L;
inorganic salts: 1.0-30.0 g/L;
preservative: 0.1-10.0 g/L.
In some embodiments, the protein C activity assay kit includes reagent R1 and reagent R2,
the reagent R1 comprises:
HEPES buffer solution: 5.0-30.0 g/L;
protein C activator: 0.05-0.50 IU/ml;
bovine serum albumin: 5.0-30.0 g/L;
trehalose: 0.5-20.0 g/L;
PEG-20000：0.5～15.0g/L；
PC300：0.5～10.0mL/L；
triethanolamine: 10-30 mL/L;
the reagent R2 comprises:
HEPES buffer solution: 5.0-30.0 g/L;
chromogenic substrate: 0.1-0.8 mg/ml;
arginine: 1.0-20.0 g/L;
cesium chloride: 1.0-30.0 g/L;
preservative: 0.1-10.0 g/L.
In another aspect, the present invention provides a method for preparing a protein C activity assay kit, comprising the following steps:
preparation of reagent R1: mixing a protein C activator, a buffer solution, polyethylene glycol, PC300 and an alcohol amine compound, and adjusting the pH value to 7.2-8.5;
preparation of reagent R2: mixing the chromogenic substrate and the buffer solution, and adjusting the pH value to 6.0-7.2.
In the above-mentioned method for preparing a protein C activity assay kit, PC300, i.e., proClin300, is used in an exemplary amount of 0.5 to 10.0mL/L, and for example, 0.5mL/L, 1mL/L, 2mL/L, 3mL/L, 4mL/L, 5mL/L, 6mL/L, 7mL/L, 8mL/L, 9mL/L, or 10mL/L can be selected.
In the above method for preparing the protein C activity assay kit, the protein C activator is a component extracted from Agkistrodon halys venom and capable of specifically activating protein C. Exemplary amounts of protein C activator are 0.05 to 0.50IU/ml, and may be, for example, 0.05IU/ml, 0.1IU/ml, 0.15IU/ml, 0.2IU/ml, 0.25IU/ml, 0.3IU/ml, 0.35IU/ml, 0.4IU/ml, 0.45IU/ml, or 0.5IU/ml.
In the preparation method of the protein C activity assay kit, the polyethylene glycol is selected from one or the combination of more than two of PEG-20000, PEG-4000 and PEG-6000. In a further preferred embodiment, the polyethylene glycol is PEG-20000. Polyethylene glycol is illustratively used in an amount of 0.5 to 15.0g/L, and may be, for example, 0.5g/L, 1g/L, 2g/L, 3g/L, 4g/L, 5g/L, 6g/L, 7g/L, 8g/L, 9g/L, 10g/L, 11g/L, 12g/L, 13g/L, 14g/L, or 15g/L.
In the method for preparing the protein C activity assay kit, the alcohol amine compound is one or a combination of two or more selected from tromethamine, 2-amino-2-methyl-1-propanol, monoethanolamine, diethanolamine, triethanolamine, 3-propanolamine, monoisopropanolamine, diisopropanolamine, triisopropanolamine, N-dimethylethanolamine and N, N-diethylethanolamine. In a further preferred embodiment, the alkanolamine compound is one or a combination of two or more selected from the group consisting of tromethamine, triethanolamine and 2-amino-2-methyl-1-propanol. In a further preferred embodiment, the alkanolamine compound is triethanolamine. The alkanolamine compound is illustratively used in an amount of 1 to 40g/L, and may be, for example, 1g/L, 3g/L, 5g/L, 7g/L, 8g/L, 9g/L, 10g/L, 11g/L, 12g/L, 13g/L, 14g/L, 15g/L, 16g/L, 17g/L, 18g/L, 19g/L, 20g/L, 21g/L, 22g/L, 23g/L, 24g/L, 25g/L, 26g/L, 27g/L, 28g/L, 29g/L, 30g/L, 32g/L, 34g/L, 36g/L, 38g/L, 39g/L, 40g/L.
In the above method for preparing the protein C activity assay kit, the buffer solution used in the preparation of the reagent R1 and the reagent R2 is one or a combination of two or more selected from HEPES acid buffer, tris buffer, imidazole buffer, and barbiturate buffer. An exemplary amount of buffer is 5.0 to 30.0g/L.
In the above method for preparing the protein C activity assay kit, the stabilizing agent used in preparing the reagent R1 may be one or a combination of two or more selected from proteins, saccharides, amino acids, antioxidants, and suspending agents. In a more preferred embodiment, the stabilizer is selected from one or a combination of two or more of bovine serum albumin, trehalose, mannitol and sorbitol. In a further preferred embodiment, the stabilizer is a combination of bovine serum albumin and trehalose. The amount of stabilizer is conventional in the art, for example, bovine serum albumin is illustratively used in an amount of 5.0 to 30.0g/L, and trehalose is illustratively used in an amount of 0.5 to 20.0g/L.
In the above-mentioned method for preparing a kit for measuring protein C activity, the chromogenic substrate in the reagent R2 is one selected from PyroGlu-Pro-Arg-pNA HCl, p-glu-Pro-Arg-MNA and THC-Pro-Arg-pNA, and the chromogenic substrate is used in an exemplary amount of 0.1 to 0.8mg/ml.
In another aspect, the present invention provides a method for preparing a protein C activity assay kit, comprising the following steps:
preparation of reagent R1: mixing a protein C activator, a buffer solution, bovine serum albumin, trehalose, PEG-20000, PC300 and triethanolamine, and adjusting the pH value to 7.2-8.5;
preparation of reagent R2: mixing a chromogenic substrate, a buffer solution, a stabilizer, inorganic salt and a preservative, and adjusting the pH value to 6.0-7.2;
wherein, the buffer solution in the reagent R1 and the reagent R2 is selected from one or the combination of more than two of HEPES acid buffer solution, tris buffer solution, imidazole buffer solution and barbital buffer solution.
In certain embodiments, an exemplary amount of protein C activator in agent R1 is 0.05 to 0.50IU/ml, and may be, for example, 0.05IU/ml, 0.1IU/ml, 0.15IU/ml, 0.2IU/ml, 0.25IU/ml, 0.3IU/ml, 0.35IU/ml, 0.4IU/ml, 0.45IU/ml, or 0.5IU/ml.
In certain embodiments, the buffer in reagent R1 is HEPES buffer in an amount of 5.0 to 30.0g/L.
In some embodiments, the bovine serum albumin is typically present in the reagent R1 in an amount of 5.0 to 30.0g/L, and the trehalose is typically present in an amount of 0.5 to 20.0g/L.
In certain embodiments, PEG-20000 in the reagent R1 is illustratively used in an amount of 0.5 to 15.0g/L, e.g., 0.5g/L, 1g/L, 2g/L, 3g/L, 4g/L, 5g/L, 6g/L, 7g/L, 8g/L, 9g/L, 10g/L, 11g/L, 12g/L, 13g/L, 14g/L, or 15g/L.
In certain embodiments, PC300, proClin300, in reagent R1 is used in an exemplary amount of 0.5 to 10.0mL/L, e.g., 0.5mL/L, 1mL/L, 2mL/L, 3mL/L, 4mL/L, 5mL/L, 6mL/L, 7mL/L, 8mL/L, 9mL/L, 10mL/L can be selected.
In certain embodiments, an exemplary amount of triethanolamine in reagent R1 is 10 to 30mL/L, and can be, for example, 10mL/L, 12mL/L, 14mL/L, 15mL/L, 17mL/L, 19mL/L, 20mL/L, 22mL/L, 24mL/L, 26mL/L, 28mL/L, 30mL/L.
In certain embodiments, the chromogenic substrate in reagent R2 is selected from one of PyroGlu-Pro-Arg-pNA. HCl, p-glu-Pro-Arg-MNA, THC-Pro-Arg-pNA, with an exemplary amount of chromogenic substrate in the range of 0.1 to 0.8mg/ml.
In certain embodiments, the buffer in reagent R2 is HEPES buffer. An exemplary amount of buffer in reagent R2 is 5.0 to 30.0g/L.
In some embodiments, the stabilizing agent in the reagent R2 may be selected from one or a combination of two or more of proteins, saccharides, amino acids, antioxidants, and suspending agents, wherein the proteins may be bovine serum albumin; the saccharide can be trehalose, mannitol, sorbitol, etc., and the amino acid can be histidine, arginine, etc. In certain embodiments, the stabilizing agent in agent R2 is arginine. Exemplary amounts of the stabilizer are 1.0 to 20.0g/L.
In certain embodiments, the preservative in agent R2 may be selected from one or more of the sodium azide (Na 3N), MIT (i.e., 2-methyl-4-isothiazolin-3-one), CMIT (i.e., 5-chloro-2-methyl-4-isothiazolin-3-one), phenol, proClin series. In certain embodiments, the preservative in reagent R2 is sodium azide. Exemplary amounts of preservatives are 0.1 to 10.0g/L.
Advantageous effects
The protein C activity determination kit provided by the invention has the advantages of obviously improved stability and anti-hemoglobin interference effect. The kit is a liquid kit, and because the reagent R1 and the reagent R2 in the kit are both liquid, freeze drying is not needed, the preparation process is simpler, and the production cost is reduced; before the actual use of the kit, the redissolution operation is not needed, the use is more convenient, and the difference between bottles is reduced.
The protein C activity determination kit provided by the invention is simple to prepare, low in cost, good in stability and convenient to use, and can be widely applied to institutions such as hospitals, health departments, medical biological research institutions and the like.
Detailed Description
The present invention will be described in detail below with reference to specific embodiments and examples, and the advantages and various effects of the present invention will be more clearly apparent therefrom. It will be understood by those skilled in the art that these specific embodiments and examples are for the purpose of illustrating the invention and are not to be construed as limiting the invention.
Example 1: preparation of protein C activity determination kit
The preparation of the protein C activity assay kit was performed according to table 1-table 3:
TABLE 1
TABLE 2
TABLE 3
Example 2: stability study of protein C Activity assay kit
An experimental instrument: SYSMEX CS-2100i full-automatic coagulation analyzer
Quality control of plasma: normal quality Control Plasma (Control Plasma N) and abnormal quality Control Plasma (Control Plasma P)
And (3) experimental operation:
the protein C activity assay kit of the experimental groups 1 to 7 in the example 1 is used for respectively assaying the protein C activity of two quality control blood plasmas, and the obtained assay value is an initial assay value;
the protein C activity assay kit of the experimental groups 1 to 7 is placed in an environment at 37 ℃ for thermal destruction, and after the thermal destruction is performed for a certain time (for example, 1 day, 3 days, 7 days, 10 days, 14 days), the protein C activity is assayed for two kinds of quality control plasma respectively to obtain assay values under different thermal destruction times;
the relative deviation of the measured value after thermal destruction and the initial measured value was calculated, and it was considered that the relative deviation was within. + -. 10%.
The stability results of the protein C activity assay kits of experimental groups 1-5 and 7 are shown in table 4:
(since the kit calibration curve signal values of the experimental group 6 were entirely low and could not satisfy the clinical requirements, the stability test results thereof were not recorded in Table 4)
TABLE 4
In table 4, control levels 1 and 2 represent samples of two different protein C activities, respectively, control level N represents a normal level, control level P represents an abnormal level, and each level was averaged over 3 replicates. As can be seen from Table 4, the protein C activity assay kits of experimental groups 1-3 showed a relative deviation of the measured activity value from the initial measured value of more than 10% after 10 days of thermal destruction (37 ℃), indicating that the stability of the kits of experimental groups 1-3 was poor. The protein C activity determination kit of the experimental group 7 has the advantage that after 14 days of thermal destruction (37 ℃), the relative deviation of abnormal quality control plasma is less than +/-2.5%, and the kit has the best thermal stability effect.
Furthermore, the inventors also replaced triethanolamine in the reagent R1 of Experimental group 7 with tromethamine (amount: 10.519 g/L) or triethanolamine in the reagent R1 of Experimental group 7 with 2-amino-2-methyl-1-propanol (amount: 3.2 mL/L) based on the kit formulation of Experimental group 7, and the other ingredients were the same as those of Experimental group 7. Then, the two alternative kits were subjected to stability examination in the same manner as in example 2, and the stability effect was equivalent to that of experiment group 7.
Example 3: stability study of commercially available protein C Activity assay kit
After redissolving a commercially available protein C activity measurement kit (chromogenic substrate method), the stability of the redissolved liquid reagent was tested according to the method of example 2, and the stability results are shown in table 5:
TABLE 5
As can be seen from table 5: the commercial protein C activity assay kit is lyophilized powder, and after the lyophilized powder is redissolved, the relative deviation of abnormal quality control plasma of the kit in a solution state is > +/-10% after the kit is thermally damaged (37 ℃) for 10 days, namely the stability after the kit is placed for 10 days is poor.
Example 4: examination of anti-hemoglobin interference effects
The experimental group 7 and the commercially available protein C activity measurement kit were subjected to examination of the anti-hemoglobin interference effect:
(1) Preparation of hemoglobin sample: preparing a high-concentration hemoglobin mother solution (5.0 g/L), proportionally adding the mother solution into mixed plasma (human normal plasma within 4 hours, and matrix effect is removed by using 0.9% physiological saline), and respectively preparing hemoglobin-containing samples with the concentrations of 0.0 (namely the mixed plasma), 1.0, 2.0, 3.0, 4.0 and 5.0g/L;
(2) The test group 7 and the commercially available protein C activity measurement kit are used respectively to perform the measurement according to the hemoglobin content in the sample from small to large, and the relative deviation (i.e. the change rate) between the measurement results of the samples with the hemoglobin concentrations of 1.0, 2.0, 3.0, 4.0 and 5.0g/L and the sample with the hemoglobin content of 0.0g/L is calculated respectively, wherein the relative deviation is regarded as qualified within ± 10%, and the smaller the relative deviation is, the smaller the influence of the measurement results on the hemoglobin in the sample is, the better the anti-hemoglobin interference ability of the reagent is.
The results of anti-hemoglobin interference are shown in table 6:
TABLE 6
As can be seen from table 6: when the kit is used for detecting a sample with the hemoglobin content of less than or equal to 5.0g/L, the detection result is stable, and the relative deviation is small and is within +/-10%; and when the commercially available kit detects a sample with the hemoglobin content of 3.0g/L, the relative deviation starts to be maintained above 10%, and when the hemoglobin content is 4.0 and 5.0g/L, the detection curve fluctuates violently due to serious interference, and the result cannot be measured.
Example 5: correlation study of random plasma sample detection
Plasma samples were collected randomly from normal and patient for 33 out of 17 men and 16 women. The present invention was repeated 2 times for each sample using the kit of the present invention (experimental group 7 in example 1) and the protein C assay kit (chromogenic substrate method) of Siemens, germany, having a product number of OUVV15, and the measurement mean value, the correlation coefficient between the two values were calculated, and linear regression was performed.
And (3) detection results: the correlation coefficient r =0.997 and the linear regression equation is y =0.9637x +5.3915 for both kits. It follows from the requirements r > 0.975 of the U.S. clinical laboratory standardization organization (CLSI) document: the detection result of the kit provided by the invention is consistent with that of a protein C detection kit (chromogenic substrate method) of Siemens company in Germany.
Claims (13)
1. The protein C activity determination kit is characterized by comprising a reagent R1 and a reagent R2, wherein the reagent R1 comprises a protein C activator, a buffer solution, polyethylene glycol, PC300 and an alcamines compound; the reagent R2 comprises a chromogenic substrate and a buffer; the polyethylene glycol is selected from one or more of PEG-20000, PEG-4000 and PEG-6000; the dosage of the polyethylene glycol is 0.5-15.0 g/L;
the alcohol amine compound is selected from one or the combination of more than two of tromethamine, 2-amino-2-methyl-1-propanol, monoethanolamine, diethanolamine, triethanolamine, 3-propanolamine, monoisopropanolamine, diisopropanolamine, triisopropanolamine, N-dimethylethanolamine and N, N-diethylethanolamine; the dosage of the alcohol amine compound is 1-40 g/L.
2. The kit for measuring protein C activity according to claim 1, wherein the pH of said reagent R1 is 7.2 to 8.5.
3. The kit for measuring protein C activity according to claim 2, wherein the pH value of the reagent R1 is 7.2 to 7.6.
4. The kit for measuring protein C activity according to claim 1, wherein the protein C activator is a protein C activator extracted from Agkistrodon halys venom in an amount of 0.05-0.50 IU/ml.
5. The protein C activity assay kit according to claim 1, wherein said polyethylene glycol is PEG-20000; the dosage of the PEG-20000 is 0.5-15.0 g/L.
6. The kit for measuring protein C activity according to claim 1, wherein said alcohol amine compound is one or a combination of two or more selected from the group consisting of tromethamine, triethanolamine and 2-amino-2-methyl-1-propanol.
7. The protein C activity assay kit according to claim 1, wherein said alcamines are triethanolamine.
8. The kit for measuring the activity of protein C according to claim 1, wherein the buffer solution in the reagent R1 and the reagent R2 is one or a combination of two or more selected from the group consisting of HEPES acid buffer solution, tris buffer solution, imidazole buffer solution and barbiturate buffer solution.
9. The kit for measuring protein C activity according to claim 1, wherein the chromogenic substrate in the reagent R2 is one selected from the group consisting of PyroGlu-Pro-Arg-pNA-HCl, p-glu-Pro-Arg-MNA, and THC-Pro-Arg-pNA.
10. The protein C activity assay kit according to any one of claims 1 to 9, wherein the kit comprises a reagent R1 and a reagent R2;
the reagent R1 comprises:
HEPES buffer solution: 5.0-30.0 g/L;
protein C activator: 0.05-0.50 IU/ml;
bovine serum albumin: 5.0-30.0 g/L;
trehalose: 0.5-20.0 g/L;
PEG-20000：0.5～15.0g/L；
PC300：0.5～10.0mL/L；
triethanolamine: 10-30 mL/L;
the reagent R2 comprises:
HEPES buffer solution: 5.0-30.0 g/L;
chromogenic substrate: 0.1-0.8 mg/ml;
a stabilizer: 1.0-20.0 g/L;
inorganic salts: 1.0-30.0 g/L;
preservative: 0.1-10.0 g/L.
11. A protein C activity assay kit, comprising a reagent R1 and a reagent R2;
the reagent R1 comprises:
HEPES buffer solution: 5.0-30.0 g/L;
protein C activator: 0.05-0.50 IU/ml;
bovine serum albumin: 5.0-30.0 g/L;
trehalose: 0.5-20.0 g/L;
PEG-20000：0.5～15.0g/L；
PC300：0.5～10.0mL/L；
triethanolamine: 10-30 mL/L;
the reagent R2 comprises:
HEPES buffer solution: 5.0-30.0 g/L;
chromogenic substrate: 0.1-0.8 mg/ml;
arginine: 1.0-20.0 g/L;
cesium chloride: 1.0-30.0 g/L;
preservative: 0.1-10.0 g/L.
12. A preparation method of a protein C activity assay kit is characterized by comprising the following steps:
preparation of reagent R1: mixing a protein C activator, a buffer solution, a stabilizer, polyethylene glycol, PC300 and an alcohol amine compound, and adjusting the pH value to 7.2-8.5;
preparation of reagent R2: mixing a chromogenic substrate and a buffer solution, and adjusting the pH value to 6.0-7.2;
wherein the polyethylene glycol is selected from one or more of PEG-20000, PEG-4000 and PEG-6000; the dosage of the polyethylene glycol is 0.5-15.0 g/L;
the alcohol amine compound is selected from one or the combination of more than two of tromethamine, 2-amino-2-methyl-1-propanol, monoethanolamine, diethanolamine, triethanolamine, 3-propanolamine, monoisopropanolamine, diisopropanolamine, triisopropanolamine, N-dimethylethanolamine and N, N-diethylethanolamine; the dosage of the alcamines compound is 1-40 g/L.
13. A preparation method of a protein C activity assay kit is characterized by comprising the following steps:
preparation of reagent R1: mixing a protein C activator, a buffer solution, bovine serum albumin, trehalose, PEG-20000, PC300 and triethanolamine, and adjusting the pH value to 7.2-8.5;
preparation of reagent R2: mixing a chromogenic substrate, a buffer solution, a stabilizer, inorganic salt and a preservative, and adjusting the pH value to 6.0-7.2; wherein, the buffer solution in the reagent R1 and the reagent R2 is selected from one or the combination of more than two of HEPES acid buffer solution, tris buffer solution, imidazole buffer solution and barbital buffer solution;
the dosage of the PEG-20000 is 0.5 to 15.0g/L;
the dosage of the triethanolamine is 1 to 40g/L.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911138203.6A CN110714051B (en) | 2019-11-20 | 2019-11-20 | Protein C activity determination kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911138203.6A CN110714051B (en) | 2019-11-20 | 2019-11-20 | Protein C activity determination kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110714051A CN110714051A (en) | 2020-01-21 |
| CN110714051B true CN110714051B (en) | 2023-04-07 |
Family
ID=69216170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911138203.6A Active CN110714051B (en) | 2019-11-20 | 2019-11-20 | Protein C activity determination kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110714051B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113913491B (en) * | 2021-10-10 | 2023-09-29 | 青岛大学附属医院 | Method for measuring protein C activity, reagent for measuring protein C activity, and method for producing the same |
| CN114814245A (en) * | 2022-06-30 | 2022-07-29 | 深圳市帝迈生物技术有限公司 | Protein C activity determination kit based on chromogenic substrate method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5001069A (en) * | 1986-03-07 | 1991-03-19 | Boehringer Mannheim Gmbh | Process for photometric determination of protein C and/or protein S |
| CN1245434A (en) * | 1996-12-24 | 2000-02-23 | 拜奥根有限公司 | Stable liquid interferon formulations |
| CN102692511A (en) * | 2012-06-08 | 2012-09-26 | 上海太阳生物技术有限公司 | Kit (Developing substrate method) for testing protein C (PC) |
-
2019
- 2019-11-20 CN CN201911138203.6A patent/CN110714051B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5001069A (en) * | 1986-03-07 | 1991-03-19 | Boehringer Mannheim Gmbh | Process for photometric determination of protein C and/or protein S |
| CN1245434A (en) * | 1996-12-24 | 2000-02-23 | 拜奥根有限公司 | Stable liquid interferon formulations |
| CN102692511A (en) * | 2012-06-08 | 2012-09-26 | 上海太阳生物技术有限公司 | Kit (Developing substrate method) for testing protein C (PC) |
Non-Patent Citations (4)
| Title |
|---|
| Establishment of a new protein C detection system based on chromogenic substrate assay and its clinical diagnostic value for deep vein thrombosis;Wenfei Lu 等;《J Clin Lab Anal》;20211231;第35卷;第1-11页 * |
| Fast functional assay of protein C in whole plasma using a snake venom activator: evaluation in patients with congenital and acquired protein C deficiencies;Hoyu Takahashi 等;《Clinica Chimicu Acta》;19881231;第175卷;第217-226页 * |
| 蝮蛇毒作激活剂的发色底物比色法测定人血浆蛋白C活性;瞿国伟 等;《中 国《 蛇 志 》杂 志》;19950630;第7卷(第2期);第4-5页 * |
| 马振友 等.西医皮肤外用制剂手册.《西医皮肤外用制剂手册》.河南科学技术出版社,2019,(第1版),第262页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110714051A (en) | 2020-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2955345B2 (en) | Endotoxin kinetic assay using Limulus amoebocyte lysate and chromogenic substrate | |
| US20190390248A1 (en) | Serum preparation | |
| US6902904B2 (en) | Coagulation assay reagents containing lanthanides | |
| CN107748267B (en) | A kind of kit measuring activated partial thromboplastin time (APTT) | |
| CN110714051B (en) | Protein C activity determination kit | |
| US11460477B2 (en) | Two component “mix and use” liquid thromboplastin reagent, methods of making, and methods of use thereof | |
| US7294479B2 (en) | Compositions, kit and one-step method for monitoring compounds having anti-factor Xa and/or anti factor IIa activities | |
| White et al. | Assessment of lumiaggregometry for research and clinical laboratories | |
| CN109082458B (en) | Kit for quantitatively detecting oral blood coagulation factor Xa inhibitor by using thrombus elastography method and preparation method of kit | |
| EP0107383B1 (en) | Diagnostic activated partial thromboplastin reagent | |
| Zacharski et al. | Standardization of the one-stage assay for factor VIII (antihemophilic factor) | |
| CN116410258A (en) | Factor XI deficiency plasma protective agent and application thereof | |
| JPH0630633B2 (en) | Method for detecting allergy, reagent and device suitable for the method, and method for measuring drug for allergy and anti-inflammatory agent | |
| Nishida et al. | A new rapid and simple assay for factor XIII activity using dansylcadaverine incorporation and gel filtration | |
| CA2039173C (en) | Factor ix chromogenic assay | |
| CN112557665A (en) | Confirmation reagent for lupus anticoagulant and preparation method thereof | |
| van den Besselaar et al. | Influence of blood collection systems on the prothrombin time and international sensitivity index determined with human and rabbit thromboplastin reagents | |
| CN106434610B (en) | Thrombin solution | |
| CN106337044B (en) | Thrombin solution | |
| CN110133304B (en) | Composition, reagent containing the composition and application thereof | |
| Jensen et al. | Influence of freeze-drying on the clotting properties of fibrinogen in plasma | |
| KR20200118428A (en) | How to use activated carbon to diagnose hemostatic disorder | |
| Maki | Pathophysiology of Plasmin System I. Routine Measuring Method of Plasmin System in This Clinic | |
| JP2021192009A (en) | Fibrinogen measurement method | |
| Meijer et al. | An improved method for the detection of α2-antiplasmin activity on the automated coagulation analyzer MLA Electra 1000C |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |